Page 355 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Other publications (not in thesis)
Lunenburg CATC, Henricks LM, van Kuilenburg ABP, Mathijssen RHJ, Schellens JHM, Gelderblom H, Guchelaar HJ, Swen JJ. Diagnostische en therapeutische strategie voor fluoropyrimidines bij patiënten die meerdere DPYD-varianten dragen. Ned Tijdschr Oncol. 2019; 16:109-14.
Henricks LM, Lunenburg CATC, Cats A, Mathijssen RHJ, Guchelaar HJ, Schellens JHM. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? - Authors’ reply. Lancet Oncol. 2019 Feb;20(2):e67
Lunenburg CATC, Swen JJ. PGx monografie NVZA – DPYD/Dihydropyrimidine Dehydrogenase. Available online (tdm-monografie.org) November 15, 2018
Henricks LM, Kienhuis E, de Man FM, van der Veldt AAM, Hamberg P, van Kuilenburg ABP, van Schaik RHN, Lunenburg CATC, Guchelaar HJ, Schellens JHM, Mathijssen RHJ. Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine. JCO Precis Oncol. Published online Oct 6, 2017.
Lunenburg CATC, Swen JJ, Guchelaar HJ, Gelderblom H. J Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. Gastrointest Cancer. 2017 Mar;48(1):117-118. (Letter to the Editor)
Lunenburg CATC*, Henricks LM*, Meulendijks D, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JM. De Alpe-DPD-studie: geïndividualiseerd doseren van fluoropyrimidines door middel van DPYD-genotypering en exploratieve fenotypering. Ned Tijdschr Oncol. 2016; 13(1):24-6.
In preparation
Lunenburg CATC, Henricks LM, Böhringer S, de Man FM, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Gelderblom H, Mathijssen RHJ, Cats A, Guchelaar HJ, Schellens JHM, Swen JJ. Genome-wide association study to discover novel genetic variants related to the onset of severe toxicity following fluoropyrimidine use. Manuscript in preparation.
Lunenburg CATC*, Henricks LM*, de Man FM*, Meulendijks D, van Kuilenburg ABP, Maring JG, van Staveren MC, de Vries N, Rosing H, Beijnen JH, Pluim D, Modak A, Imholz ALT, Schellens JHM, Swen JJ, Gelderblom H, Cats A, Mathijssen RHJ, Guchelaar HJ. Comparison of four phenotyping assays for predicting dihydropyrimidine dehydrogenase (DPD) deficiency and severe fluoropyrimidine-induced toxicity: a clinical study. Manuscript in preparation.
A
Appendix
353